| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | GALT;;GALT |
| WB Predicted band size | 43 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human GALT |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于GALT(Galactose-1-Phosphate Uridylyltransferase)抗体的参考文献示例(内容为虚构，仅作格式参考)：
1. **"Development of a novel monoclonal antibody against human GALT for galactosemia diagnosis"**
*作者：Smith J, et al.*
*摘要：* 研究开发了一种高特异性单克隆抗体，用于检测GALT酶活性缺失导致的半乳糖血症。通过ELISA和Western blot验证抗体灵敏度，证实其在新生儿筛查中的应用潜力。
2. **"Autoantibodies targeting GALT in autoimmune disorders: A cross-sectional study"**
*作者：Lee H, et al.*
*摘要：* 在系统性红斑狼疮和类风湿性关节炎患者中首次发现抗GALT自身抗体，提示其可能参与代谢异常相关的自身免疫病理机制，为疾病生物标志物研究提供新方向。
3. **"Immunohistochemical localization of GALT in intestinal lymphoid tissue using polyclonal antibodies"**
*作者：Garcia R, et al.*
*摘要：* 通过兔源多克隆抗体标记肠道相关淋巴组织(GALT)中的M细胞和派伊尔结，揭示GALT在黏膜免疫应答中的空间分布特征，为肠道免疫研究提供工具。
4. **"CRISPR/Cas9-mediated GALT knockout cell lines validated by antibody-based protein analysis"**
*作者：Wang Y, et al.*
*摘要：* 利用抗GALT抗体验证基因编辑细胞系中GALT蛋白的表达缺失，建立半乳糖血症体外模型，为酶替代疗法的药物筛选提供平台。
(注：以上文献为示例性质，实际文献需通过PubMed/Google Scholar检索关键词如"GALT antibody"、"anti-GALT autoantibody"等获取。)
GALT (Galactose-1-phosphate uridylyltransferase) antibodies are primarily associated with research and diagnostic applications targeting galactosemia, a rare autosomal recessive metabolic disorder. GALT is a critical enzyme in the Leloir pathway, catalyzing the conversion of galactose-1-phosphate and UDP-glucose to UDP-galactose and glucose-1-phosphate. Mutations in the GALT gene lead to enzyme deficiency, causing classic galactosemia, characterized by life-threatening symptoms in newborns exposed to dietary galactose.
Anti-GALT antibodies are developed as tools to study enzyme expression, localization, and function in cellular models. They enable detection of GALT protein levels via techniques like Western blot, ELISA, or immunohistochemistry, aiding in diagnosing galactosemia and distinguishing between variants (e.g., Duarte mutation). These antibodies also facilitate research into genotype-phenotype correlations, as residual enzyme activity influences disease severity.
In clinical settings, GALT antibodies support newborn screening programs by confirming positive metabolic tests. Additionally, they contribute to therapeutic research, such as evaluating enzyme replacement therapies or gene-editing strategies. However, challenges remain in standardizing antibody specificity across GALT isoforms and mutant forms. Continued development of high-affinity, mutation-specific antibodies may improve diagnostic accuracy and mechanistic insights into galactosemia pathology.
×
